Funding for this research was provided by:
Korea Medical Device Development Fund (HI20C1662, 1711138358, KMDF_PR_20200901_0173)
Patient-Centered Clinical Research Coordinating Center (HC21C0028)
Received: 18 September 2022
Accepted: 20 October 2022
First Online: 17 November 2022
: This study was approved by both the governed official review committee and the institutional review board at Seoul National University Hospital (E-2205-006-1320). Because anonymous and deidentified information was used for analysis, informed consent was waived.
: Not applicable.
: N.Y.B., S.-R.L., H.J.A., H.-J.A., S.K., K.-D.H., K.-N.L., S.O.: None. E.-K.C.: Research grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical Co., Daiichi-Sankyo, DeepQure, Dreamtech Co., Ltd., Jeil Pharmaceutical Co. Ltd, Medtronic, Samjinpharm, Seers Technology, and Skylabs. G.Y.H.L.: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo. No personal fees were received.